This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Radiation Therapy  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 109 words of the full text and any section headings.

To the Editor: In her Medical News & Perspectives article, Dr Hampton¹ stated, "Medicare reimbursement for radioimmunotherapy was recently cut, and Medicare payments will fall $10 000 short of the cost for each patient treated. . . . " Although the Centers for Medicare & Medicaid Services (CMS) reduced payment for radioimmunotherapeutics in its final reimbursement rulings for 2008, Congress reversed the CMS ruling. It mandated through the Medicare, Medicaid, and SCHIP Extension Act of 2007 that radiopharmaceutical reimbursement rates be kept at current (2007) levels through the first half of 2008.²

Financial Disclosures: Dr Singer is a full-time employee, chief medical officer, and equity holder in Cell Therapeutics, the US marketer of Y-ibritumomab.

Jack W. Singer, MD
jsinger@ctiseattle.com
Cell Therapeutics Inc
Seattle, Washington

1. Hampton T. Phase 3 trials suggest ways to improve current hematologic cancer therapies. JAMA. 2008;299(5):510-512. FREE FULL TEXT 2. Medicare, Medicaid, and SCHIP Extension Act of 2007. Pub L No. 110-173 (December 29, 2007). 106.

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2008;299(21):2512.

RELATED ARTICLE

Phase 3 Trials Suggest Ways to Improve Current Hematologic Cancer Therapies
Tracy Hampton
JAMA. 2008;299(5):510-512.
EXTRACT | FULL TEXT  

RELATED LETTER

Radiopharmaceutical Reimbursement Rates—Reply
Tracy Hampton
JAMA. 2008;299(21):2512-2513.
EXTRACT | FULL TEXT